Davita Clinical Research
Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers
  • Home >
  • About Us >
    • Leadership >
    • Careers >
      • Our Culture >
      • Diversity & Belonging >
    • Our History >
    • Awards and Recognition >
  • Services >
    • Late Phase Renal Research (ESKD) >
    • Alliance Site Network >
    • International Trials >
  • News >
    • Press Releases >
    • Events >
  • Resources >
    • Blog >
    • Video Library >
  • Contact Us >
    • For Sponsors >
    • For Investigators >
    • For Participants >
  • Home
  • About Us
    • Leadership
    • Careers
      • Our Culture
      • Diversity & Belonging
    • Our History
    • Awards and Recognition
  • Services
    • Late Phase Renal Research (ESKD)
    • Alliance Site Network
    • International Trials
  • News
    • Press Releases
    • Events
  • Resources
    • Blog
    • Video Library
  • Contact Us
    • For Sponsors
    • For Investigators
    • For Participants
  • Search this site

  • Home
  • Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers

Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers

Posted by:

Miceli JJ, Wilner KD, Swan SK, Tensfeldt TG. J Clin Pharmacol. 2005;45(6):620-630. Read more

Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment

Posted by:

Shi J, Chapel S, Montay G, Hardy P, Barrett JS, Sica D, et al. Int J Clin Pharmacol Ther. 2005;43(3):123-133. Read more

Pharmacokinetics of etoricoxib in patients with renal impairment

Posted by:

Agrawal NG, Matthews CZ, Mazenko RS, Kline WF, Woolf EJ, Porras AG, et al. J Clin Pharmacol. 2004;44(1):48-58. Read more

The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients

Posted by:

Grossman EB, Swan SK, Muirhead GJ, Gaffney M, Chung M, DeRiesthal H, et al.  Kidney Int. 2004;66(1):367-74. Read more

A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients.

Posted by:

Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. J Am Soc Nephrol. 2004;15(2):442-53. Read more

Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients

Posted by:

Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Am J Clin Nutr. 2004;80(2):299-307. Read more

Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients

Posted by:

Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G.  Nephrol Dial Transplant. 2004;19(6):1507-19. Read more

A low serum iron level is a predictor of poor outcome in hemodialysis patients

Posted by:

Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD.  Am J Kidney Dis. 2004;43(4):671-84. Read more

A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease

Posted by:

Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, et al. Kidney Int. 2004;66(6):2446-2453. Read more

Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment

Posted by:

Shi J, Montay G, Chapel S, Hardy P, Barrett JS, Sack M, et al. J Clin Pharmacol. 2004;44(3):234-244. Read more

Categories

  • Blog
  • Events
  • Press Releases
  • Video

Blog: A Guide to Different Models of SMOs

Navigate
  • Home
  • About Us
  • Services
  • News
  • Resources
  • Contact Us
Headquarters
DaVita Clinical Research®
6600 France Ave S Suite 660
Edina, MN 55435 (Map)
  • Telephone: 888-345-2567
  • Fax: 866-852-3241
Corporate
  • Careers
  • davita.com
  • mykidneyresearch.com
  • Renal Research FAQ
Follow us on:
  • LinkedIn
  • Twitter
  • YouTube
  • Facebook
  • © 2026 DaVita Inc.
  • Web privacy policy
  • Sitemap
  • Terms of use
x
x

View PDF